Ligand control of coregulator recruitment to nuclear receptors

Annual Review of Physiology

Volumn 67, Issue , 2005, Pages 309-333

  Nettles, Kendall W ^a   Greene, Geoffrey L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Coactivator; Corepressor; Steroid hormone; Structure

Indexed keywords

CELL NUCLEUS RECEPTOR; FULVESTRANT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RALOXIFENE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; THYROID HORMONE RECEPTOR; VITAMIN D RECEPTOR;

AMINO TERMINAL SEQUENCE; BINDING SITE; CRYSTAL STRUCTURE; DIMERIZATION; DNA RESPONSIVE ELEMENT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; GENE MUTATION; HORMONE ACTION; LIGAND BINDING; MULTIGENE FAMILY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

HUMANS; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 15544371000     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.66.032802.154710     Document Type: Review

References (132)

1. Chambon P. 1996. A decade of molecular biology of retinoic acid receptors. FASEB J. 10:940-54
2. Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell 83:841-50
3. Kliewer SA, Xu HE, Lambert MH, Willson TM. 2001. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 56:239-63
4. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-70
5. McDonnell DP, Wijayaratne A, Chang CY, Morris JD. 2002. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am. J. Cardiol. 90:35F-43F
6. McKenna NJ, O'Malley BW. 2002. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465-74
7. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, et al. 1998. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12:3343-56
8. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, et al. 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-37
9. Schulman IG, Juguilon H, Evans RM. 1996. Activation and repression by nuclear hormone receptors: hormone modulates an equilibrium between active and repressive states. Mol. Cell. Biol. 16:3807-13
10. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, et al. 1995. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378:681-89
11. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D. 2000. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell. 5:289-98
12. Bramlett KS, Wu Y, Burris TP. 2001. Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol. Endocrinol. 15:909-22
13. Wong CW, Komm B, Cheskis BJ. 2001. Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. Biochemistry 40:6756-65
14. Warnmark A, Almlof T, Leers J, Gustafsson JA, Treuter E. 2001. Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERalpha and ERbeta. J. Biol. Chem. 276:23397-404
15. Matt N, Ghyselinck NB, Wendling O, Chambon P, Mark M. 2003. Retinoic acid-induced developmental defects are mediated by RARbeta/RXR heterodimers in the pharyngeal endoderm. Development 130:2083-93
16. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, et al. 2003. Peroxisome- proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159-70
17. Mueller SO, Korach KS. 2001. Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr. Opin. Pharmacol. 1:613-19
18. Leblanc BP, Stunnenberg HG. 1995. 9-cis retinoic acid signaling: changing partners causes some excitement. Genes Dev. 9:1811-16
19. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, et al. 1997. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol. Cell. Biol. 17:2166-76
20. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. 1992. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-74
21. Leo C, Yang X, Liu J, Li H, Chen JD. 2001. Role of retinoid receptor coactivator pockets in cofactor recruitment and transcriptional regulation. J. Biol. Chem. 276:23127-34
22. Roy B, Taneja R, Chambon P. 1995. Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor alpha (RAR alpha)-, RAR beta-, or RAR gamma-selective ligand in combination with a retinoid X receptor-specific ligand. Mol. Cell Biol. 15:6481-87
23. Lala DS, Mukherjee R, Schulman IG, Koch SS, Dardashti LJ, et al. 1996. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383:450-53
24. Schulman IG, Li C, Schwabe JW, Evans RM. 1997. The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev. 11:299-308
25. Smith CL, O'Malley BW. 2004. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25:45-71
26. Jordan VC. 1992. The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 70:977-82
27. Wolf DM, Jordan VC. 1992. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol. Oncol. 45:118-28
28. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, et al. 1992. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326:852-56
29. Berry M, Metzger D, Chambon P. 1990. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9:2811-18
30. McInerney EM, Katzenellenbogen BS. 1996. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J. Biol. Chem. 271:24172-78
31. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, et al. 1994. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8:21-30
32. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, et al. 1997. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1641-47
33. Smith CL, Nawaz Z, O'Malley BW. 1997. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen 4-hydroxytamoxifen. Mol. Endocrinol. 11:657-66
34. Webb P, Nguyen P, Kushner PJ. 2003. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. J. Biol. Chem. 278:6912-20
35. Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, et al. 2002. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. USA 99:7940-44
36. Shang Y, Brown M. 2002. Molecular determinants for the tissue specificity of SERMs. Science 295:2465-68
37. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, et al. 1998. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA 95:2920-25
38. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, et al. 2003. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 278:22748-54
39. Henke BR, Consler TG, Go N, Hale RL, Hohman DR, et al. 2002. A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta. J. Med. Chem. 45:5492-505
40. Nagy L, Kao HY, Love JD, Li C, Banayo E, et al. 1999. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 13:3209-16
41. Marimuthu A, Feng W, Tagami T, Nguyen H, Jameson JL, et al. 2002. TR surfaces and conformations required to bind nuclear receptor corepressor. Mol. Endocrinol. 16:271-86
42. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, et al. 1999. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 13:3198-208
43. Hu X, Lazar MA. 1999. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402:93-96
44. Zhang J, Hu X, Lazar MA. 1999. A novel role for helix 12 of retinoid X receptor in regulating repression. Mol. Cell. Biol. 19:6448-57
45. Jung DJ, Lee SK, Lee JW. 2001. Agonist-dependent repression mediated by mutant estrogen receptor alpha that lacks the activation function 2 core domain. J. Biol. Chem. 276:37280-83
46. Yoh SM, Chatterjee VK, Privalsky ML. 1997. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol. Endocrinol. 11:470-80
47. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, et al. 2000. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J. Biol. Chem. 275:5754-59
48. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, et al. 2002. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415:813-17
49. Mi LZ, Devarakonda S, Harp JM, Han Q, Pellicciari R, et al. 2003. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 11:1093-100
50. Nettles KW, Greene GL. 2003. Nuclear receptor ligands and cofactor recruitment: is there a coactivator "on deck"? Mol. Cell. 11:850-51
51. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, et al. 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-58
52. Pike AC, Brzozowski AM, Walton J, Hubhard RE, Thorsell AG, et al. 2001. Structural insights into the mode of action of a pure antiestrogen. Structure 9:145-53
53. Levenson AS, Jordan VC. 1998. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 58:1872-75
54. Wijayaratne AL, McDonnell DP. 2001. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276:35684-92
55. Kallenberger BC, Love JD, Chatterjee VK, Schwabe JW. 2003. A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nat. Struct. Biol. 10:136-40
56. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, et al. 2002. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 9:359-64
57. Nettles KW, Sun J, Radek JT, Sheng S, Rodriguez AL, et al. 2004. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol. Cell. 13:317-27
58. Greschik H, Flaig R, Renaud JP, Moras D. 2004. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J. Biol. Chem. 279:33639-46
59. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, et al. 2001. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9:699-706
60. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, et al. 1999. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3:397-403
61. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, et al. 1999. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA 96:6102-6
62. Borngraeber S, Budny MJ, Chiellini G, Cunha-Lima ST, Togashi M, et al. 2003. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Natl. Acad. Sci. USA 100:15358-63
63. Schulman IG, Shao G, Heyman RA. 1998. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function. Mol. Cell. Biol. 18:3483-94
64. Shulman AI, Larson C, Mangelsdorf DJ, Ranganathan R. 2004. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116:417-29
65. Boiling J, Castro DS, Oberg F, Nilsson K, Perlmann T. 1997. Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation. J. Biol. Chem. 272:9443-49
66. Forman BM, Umesono K, Chen J, Evans RM. 1995. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81:541-50
67. Germain P, Iyer J, Zechel C, Gronemeyer H. 2002. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415:187-92
68. 3-activated expression of the rat osteocalcin gene. Mol. Cell Biol. 13:5907-17
69. 3 receptor- and retinoid X receptor-mediated gene activation in vivo. Mol. Cell Biol. 16:1006-16
70. Westin S, Kurokawa R, Nolle RT, Wisely GB, McInerney EM, et al. 1998. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395:199-202
71. Kersten S, Dawson MI, Lewis BA, Noy N. 1996. Individual subunits of heterodimers comprised of retinoic acid and retinoid X receptors interact with their ligands independently. Biochemistry 35:3816-24
72. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, Moras D. 2000. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J. 19:2592-601
73. Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, et al. 2000. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 5:545-55
74. Klaholz BP, Mitschler A, Belema M, Zusi C, Moras D. 2000. Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma. Proc. Natl. Acad. Sci. USA 97:6322-27
75. Klaholz BP, Mitschler A, Moras D. 2000. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J. Mol. Biol. 302:155-70
76. Klaholz BP, Renaud JP, Mitschler A, Zusi C, Chambon P, et al. 1998. Conformational adaptation of agonists to the human nuclear receptor RAR gamma. Nat. Struct. Biol. 5:199-202
77. Love JD, Gooch JT, Benko S, Li C, Nagy L, et al. 2002. The structural basis for the specificity of retinoid-X receptor-selective agonists: new insights into the role of helix H12. J. Biol. Chem. 277:11385-91
78. Nolle RT, Wisely GB, Westin S, Cobb JE, Lambert MH, et al. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-43
79. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, et al. 2001. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 98:13919-24
80. Svensson S, Ostberg T, Jacobsson M, Norstrom C, Stefansson K, et al. 2003. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 22:4625-33
81. Yang W, Rachez C, Freedman LP. 2000. Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol. Cell Biol. 20:8008-17
82. Minucci S, Leid M, Toyama R, Saint-Jeannet JP, Peterson VJ, et al. 1997. Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid-dependent gene expression. Mol. Cell. Biol. 17:644-55
83. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, et al. 1996. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3:206
84. Steinmetz AC, Renaud JP, Moras D. 2001. Binding of ligands and activation of transcription by nuclear receptors. Annu. Rev. Biophys. Biomol. Struct. 30:329-59
85. Luque I, Leavitt SA, Freire E. 2002. The linkage between protein folding and functional cooperativity: two sides of the same coin? Annu. Rev. Biophys. Biomol. Struct. 31:235-56
86. Johnson BA, Wilson EM, Li Y, Moller DE, Smith RG, Zhou G. 2000. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J. Mol. Biol. 298:187-94
87. 3 receptor permits sensitive interaction with agonists. Mol. Pharmacol. 57:1206-17
88. Beekman JM, Allan GF, Tsai SY, Tsai MJ, O'Malley BW. 1993. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol. 7:1266-74
89. Egea PF, Rochel N, Birck C, Vachette P, Timmins PA, Moras D. 2001. Effects of ligand binding on the association properties and conformation in solution of retinoic acid receptors RXR and RAR. J. Mol. Biol. 307:557-76
90. Yan X, Broderick D, Leid ME, Schimerlik MI, Deinzer ML. 2004. Dynamics and ligand-induced solvent accessibility changes in human retinoid X receptor homodimer determined by hydrogen deuterium exchange and mass spectrometry. Biochemistry 43:909-17
91. Gee AC, Carlson KE, Martini PG, Katzenellenbogen BS, Katzenellenbogen JA. 1999. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol. Endocrinol. 13:1912-23
92. Watkins RE, Davis-Searles PR, Lambert MH, Redinbo MR. 2003. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol. 331:815-28
93. Bhat RA, Stauffer B, Unwalla RJ, Xu Z, Harris HA, Komm BS. 2004. Molecular determinants of ER alpha and ER beta involved in selectivity of 16 alpha-iodo-7 beta estradiol. J. Steroid. Biochem. Mol. Biol. 88:17-26
94. Gaido KW, Leonard LS, Maness SC, Hall JM, McDonnell DP, et al. 1999. Differential interaction of the methoxychlor metabolite 2,2-bis-(p- hydroxyphenyl)-1, 1,1-trichloroethane with estrogen receptors alpha and beta. Endocrinology 140:5746-53
95. Sun J, Baudry J, Katzenellenbogen JA, Katzenellenbogen BS. 2003. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. Mol. Endocrinol. 17:247-58
96. Terouanne B, Nirde P, Rabenoelina F, Bourguet W, Sultan C, Auzou G. 2003. Mutation of the androgen receptor at amino acid 708 (Gly→Ala) abolishes partial agonist activity of steroidal antiandrogens. Mol. Pharmacol. 63:791-98
97. Stanley TB, Leesnitzer LM, Montana VG, Galardi CM, Lambert MH, et al. 2003. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. Biochemistry 42:9278-87
98. Blondel A, Renaud JP, Fischer S, Moras D, Karplus M. 1999. Retinoic acid receptor: a simulation analysis of retinoic acid binding and the resulting conformational changes. J. Mol. Biol. 291:101-15
99. Farboud B, Hauksdottir H, Wu Y, Privalsky ML. 2003. Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression. Mol. Cell Biol. 23:2844-58
100. Hauksdottir H, Farboud B, Privalsky ML. 2003. Retinoic acid receptors beta and gamma do not repress, but instead activate target gene transcription in both the absence and presence of hormone ligand. Mol. Endocrinol. 17:373-85
101. Wang Z, Benoit G, Liu J, Prasad S, Aarnisalo P, et al. 2003. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423:555-60
102. Baker KD, Shewchuk LM, Kozlova T, Makishima M, Hassell A, et al. 2003. The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway. Cell 113:731-42
103. Sablin EP, Krylova IN, Fletterick RJ, Ingraham HA. 2003. Structural basis for ligand-independent activation of the orphan nuclear receptor LRH-1. Mol. Cell 11:1575-85
104. Dussault I, Lin M, Hollister K, Fan M, Termini J, et al. 2002. A structural model of the constitutive androstane receptor defines novel interactions that mediate ligand-independent activity. Mol. Cell Biol. 22:5270-80
105. Forman BM, Tzameli I, Choi HS, Chen J, Simha D, et al. 1998. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395:612-15
106. Suetsugi M, Su L, Karlsberg K, Yuan YC, Chen S. 2003. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol. Cancer Res. 1:981-91
107. Tzameli I, Pissios P, Schuetz EG, Moore DD. 2000. The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol. Cell Biol. 20:2951-58
108. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, et al. 2003. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem. 278:17277-83
109. Dhe-Paganon S, Duda K, Iwamoto M, Chi YI, Shoelson SE. 2002. Crystal structure of the HNF4 alpha ligand binding domain in complex with endogenous fatty acid ligand. J. Biol. Chem. 277:37973-76
110. Wisely GB, Miller AB, Davis RG, Thornquest AD Jr, Johnson R, et al. 2002. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure 10:1225-34
111. Kallen J, Schlaeppi JM, Bitsch F, Delhon I, Founder B. 2004. Crystal structure of the human RORalpha ligand binding domain in complex with cholesterol sulfate at 2.2 A. J. Biol. Chem. 279:14033-38
112. Kallen JA, Schlaeppi JM, Bitsch F, Geisse S, Geiser M, et al. 2002. X-ray structure of the hRORalpha LBD at 1.63 Å: structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORalpha. Structure 10:1697-707
113. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, et al. 2003. In vivo imaging of transcriptionally active estrogen receptors. Nat. Med. 9:82-86
114. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne K. 2004. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10:331S-36S
115. Benko S, Love JD, Beladi M, Schwabe JW, Nagy L. 2003. Molecular determinants of the balance between co-repressor and co-activator recruitment to the retinoic acid receptor. J. Biol. Chem. 278:43797-806
116. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, et al. 1999. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-83
117. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS. 1996. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol. 10:1388-98
118. Collingwood TN, Wagner R, Matthews CH, Clifton-Bligh RJ, Gurnell M, et al. 1998. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone. EMBO J. 17:4760-70
119. Agostini M, Gurnell M, Savage DB, Wood EM, Smith AG, et al. 2004. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology 145:1527-38
120. Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA. 1997. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36:14897-905
121. Huang HJ, Norris JD, McDonnell DP. 2002. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol. Endocrinol. 16:1778-92
122. Wolf DM, Jordan VC. 1994. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 31:129-38
123. Yamamoto Y, Wada O, Suzawa M, Yogiashi Y, Yano T, et al. 2001. The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. J. Biol. Chem. 276:42684-91
124. Schafer JI, Liu H, Tonetti DA, Jordan VC. 1999. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res. 59:4308-13
125. Levenson AS, Catherine WH, Jordan VC. 1997. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid. Biochem. Mol. Biol. 60:261-68
126. Webb P, Nguyen P, Valentine C, Weatherman RV, Scanlan TS, Kushner PJ. 2000. An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen. J. Biol. Chem. 275:37552-58
127. Chen S, Sarlis NJ, Simons SS Jr. 2000. Evidence for a common step in three different processes for modulating the kinetic properties of glucocorticoid receptor-induced gene transcription. J. Biol. Chem. 275:30106-17
128. Kurokawa R, DiRenzo J, Boehm M, Sugarman J, Gloss B, et al. 1994. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature 371:528-31
129. Wood JR, Greene GL, Nardulli AM. 1998. Estrogen response elements function as allosteric modulators of estrogen receptor conformation. Mol. Cell. Biol. 18:1927-34
130. Loven MA, Likhite VS, Choi I, Nardulli AM. 2001. Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor beta conformation. J. Biol. Chem. 276:45282-88
131. Routledge EJ, White R, Parker MG, Sumpter JP. 2000. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ER beta. J. Biol. Chem. 275:35986-93
132. Mukherjee R, Sun S, Santomenna L, Miao B, Walton H, et al. 2002. Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha. J. Steroid Biochem. Mol. Biol. 81:217-25